Entera Bio Ltd. (ENTX)
NASDAQ: ENTX · IEX Real-Time Price · USD
2.000
+0.040 (2.04%)
At close: May 1, 2024, 4:00 PM
2.050
+0.050 (2.50%)
After-hours: May 1, 2024, 5:56 PM EDT
Entera Bio Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
17
Market Cap
70.96M USD
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 0 | - | - |
Dec 31, 2022 | 134.00K | -437.00K | -76.53% |
Dec 31, 2021 | 571.00K | 206.00K | 56.44% |
Dec 31, 2020 | 365.00K | 129.00K | 54.66% |
Dec 31, 2019 | 236.00K | -264.00K | -52.80% |
Dec 31, 2018 | 500.00K | - | - |
Dec 31, 2017 | 0 | - | - |
Dec 31, 2016 | 0 | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionENTX News
- 23 days ago - Entera Bio Announces Publication of Oral PTH(1-34) Peptide Tablets (EB613) Phase 2 Trial Data in the Journal of Bone and Mineral Research - GlobeNewsWire
- 5 weeks ago - Entera Bio Announces Key Regulatory Milestone for Oral PTH(1-34) Peptide (EB613) Phase 3 Program: FDA Ruling on Qualifying BMD as a Surrogate Endpoint for Osteoporosis Drugs is Expected Within 10 Months - GlobeNewsWire
- 6 weeks ago - Entera Bio Announces Robust Pharmacokinetic Data for First-in-Class Oral GLP-2 Peptide Tablet Treatment for Patients with Short Bowel Syndrome - GlobeNewsWire
- 7 weeks ago - Entera Bio Announces Full Year 2023 Financial Results and Provides Business Updates - GlobeNewsWire
- 2 months ago - Entera Bio Regains Compliance with Nasdaq Minimum Bid Price Requirement - GlobeNewsWire
- 3 months ago - Entera Bio to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference - GlobeNewsWire
- 4 months ago - Entera Bio Receives Extension from Nasdaq to Regain Compliance with Minimum Bid Price Rule - GlobeNewsWire
- 4 months ago - Entera Bio Announces Closing of Private Placement - Extends Cash Runway into 2025 - GlobeNewsWire